Helix BioPharma Corp. (TSE:HBP – Get Free Report)’s stock price reached a new 52-week low on Tuesday. The company traded as low as C$0.94 and last traded at C$0.95, with a volume of 36861 shares traded. The stock had previously closed at C$1.14.
Helix BioPharma Stock Down 14.2%
The stock’s 50 day simple moving average is C$1.60 and its two-hundred day simple moving average is C$1.63. The firm has a market cap of C$69.50 million, a P/E ratio of -22.75 and a beta of 0.72. The company has a debt-to-equity ratio of 2.44, a current ratio of 0.45 and a quick ratio of 1.03.
Helix BioPharma Company Profile
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.
See Also
- Five stocks we like better than Helix BioPharma
- Anthropic’s IPO Could Put Amazon’s and Alphabet’s Paper Profits to the Test
- Microsoft’s AI Spending Didn’t Change—Wall Street’s View of It Did
- Cleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach
- L3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
